Literature DB >> 1839386

Lower efficacy of the dopamine D1 agonist, SKF 38393, to stimulate adenylyl cyclase activity in primate than in rodent striatum.

C Pifl1, H Reither, O Hornykiewicz.   

Abstract

The selective D1 agonist, SKF 38393, stimulated adenylyl cyclase by about 40% of basal activity in rat striatum but by only about 10% in the striatum of rhesus monkeys. In contrast, dopamine stimulated striatal adenylyl cyclase in both species with equal efficiency (70-80%). SKF 38393 30 microM inhibited the effect of 30 microM dopamine by about 45% in rat and by about 75% in primate tissue. This difference may be due to a lower D1 receptor reserve in primate than in rodent tissue and suggests that only selective D1 agonists with full efficacy at D1 receptors can be expected to have beneficial effects in patients with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1839386     DOI: 10.1016/0014-2999(91)90304-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets.

Authors:  P A Löschmann; L A Smith; K W Lange; P Jähnig; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Brain dopamine receptors: 20 years of progress.

Authors:  J W Kebabian
Journal:  Neurochem Res       Date:  1993-01       Impact factor: 3.996

3.  Cortical Serotonergic and Catecholaminergic Denervation in MPTP-Treated Parkinsonian Monkeys.

Authors:  Gunasingh Jeyaraj Masilamoni; Allison Weinkle; Stella M Papa; Yoland Smith
Journal:  Cereb Cortex       Date:  2022-04-20       Impact factor: 4.861

4.  Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.

Authors:  K K Gnanalingham; A J Hunter; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

5.  Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.

Authors:  K K Gnanalingham; D D Erol; A J Hunter; L A Smith; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

6.  The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.

Authors:  K K Gnanalingham; A J Hunter; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

7.  Morphine and naltrexone modulate D2 but not D1 receptor induced motor behavior in MPTP-lesioned monkeys.

Authors:  R J Vermeulen; B Drukarch; M C Sahadat; C Goosen; A N Schoffelmeer; E C Wolters; J C Stoof
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

8.  LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors.

Authors:  V J Watts; C P Lawler; D R Fox; K A Neve; D E Nichols; R B Mailman
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

9.  Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys.

Authors:  A F Arnsten; J X Cai; B L Murphy; P S Goldman-Rakic
Journal:  Psychopharmacology (Berl)       Date:  1994-10       Impact factor: 4.530

Review 10.  Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson's disease.

Authors:  Abdelhamid Benazzouz; Omar Mamad; Pamphyle Abedi; Rabia Bouali-Benazzouz; Jonathan Chetrit
Journal:  Front Aging Neurosci       Date:  2014-05-13       Impact factor: 5.750

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.